Silence Therapeutics (SLN) Retained Earnings (2018 - 2026)

Silence Therapeutics has disclosed Retained Earnings across 9 years of filings, most recently posting -$577.5 million for Q1 2026.

• Retained Earnings for Q1 2026 came in at -$577.5 million, down 14.92% year-over-year; the trailing twelve-month figure through Mar 2026 was -$577.5 million (down 14.92% YoY), and the FY2025 annual result was -$3.0 million, up 99.37% from the prior year.
• Retained Earnings came in at -$577.5 million for Q1 2026 at Silence Therapeutics, down from -$3.0 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$3.0 million in Q4 2025 to a low of -$577.5 million in Q1 2026.
• The 5-year median for Retained Earnings is -$488.3 million (2024), against an average of -$415.6 million.
• Across the five-year window, Retained Earnings retreated 25.39% in 2024 and jumped 99.37% in 2025, its largest moves.
• Silence Therapeutics' Retained Earnings stood at -$308.8 million in 2022, then slipped by 22.43% to -$378.1 million in 2023, then dropped by 25.39% to -$474.0 million in 2024, then surged by 99.37% to -$3.0 million in 2025, then slumped by 19306.12% to -$577.5 million in 2026.
• The last three Retained Earnings figures came in at -$577.5 million (Q1 2026), -$3.0 million (Q4 2025), and -$550.8 million (Q3 2025), per Business Quant data.